DENTSPLY SIRONA (XRAY) has returned to investors’ radar after recent trading data highlighted a mixed performance, with the stock trading near US$13 and returns differing significantly between the past month and the past year.

The recent move to a 1-month share price return of 18.26% and a year-to-date share price return of 15.53% suggests momentum in DENTSPLY SIRONA is improving, even though the 1-year total shareholder return declined 16.73% and longer-term total shareholder returns are weaker.

If DENTSPLY SIRONA’s recent rebound has you reassessing your portfolio, it can be useful to scan other healthcare technology ideas through 41 healthcare AI stocks

DENTSPLY SIRONA’s sharp 1 month rebound sits against weaker multi year returns and a share price close to analyst targets, so is the meaningful upside still ahead, or has the stock already priced in most of the recovery?

Most Popular Narrative: 71.4% Undervalued

According to the most followed narrative, DENTSPLY SIRONA’s fair value of $45.50 sits well above the recent $13.02 close, putting a spotlight on the gap between price and story.

Dentsply Sirona is built for endurance. Its business model mirrors the dental industry itself: methodical, relationship-driven, and anchored in necessity. For investors, XRAY represents exposure to healthcare demand that persists across cycles. It may never dominate headlines, but its relevance is quietly reinforced every time a patient sits in a dental chair.

If that kind of endurance based view of DENTSPLY SIRONA interests you, the full narrative goes much further into how steady procedure volumes, profit margin assumptions and future earnings power are combined to reach that fair value, and why those inputs paint such a different picture from the current share price.

Result: Fair Value of $45.50 (UNDERVALUED)

However, DENTSPLY SIRONA’s recent net loss of US$628 million and the 66% decline in 3 year total shareholder return indicate that execution and capital allocation risks are real catalysts to watch.

Next Steps

With sentiment split between DENTSPLY SIRONA’s valuation gap and its execution risks, it may be useful to move quickly and test the numbers yourself. To see what investors are optimistic about, start by reviewing the 3 key rewards.

Looking for more investment ideas beyond DENTSPLY SIRONA?

If you want to keep building on the work you have done with DENTSPLY SIRONA, use the Simply Wall St screener to uncover fresh, data driven ideas across the market.

• Zero in on potential high return opportunities early by scanning 21 elite penny stocks with strong financials before the crowd pays attention.
• Strengthen your core holdings by checking companies highlighted in the solid balance sheet and fundamentals stocks screener (49 results) so your portfolio is built on steadier financial footing.
• Stay ahead of the market by reviewing the screener containing 20 high quality undiscovered gems that could be missing from many investors’ watchlists.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.